Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients

Peiying Yang, Xiangsheng Zuo, Shailesh Advani, Bo Wei, Jessica Malek, R. Sue Day, Imad Shureiqi
doi: https://doi.org/10.1101/2020.12.02.20242214
Peiying Yang
1Departments of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ishureiq@med.umich.edu pyang@mdanderson.org
Xiangsheng Zuo
2Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
3Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shailesh Advani
4Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Wei
1Departments of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Malek
2Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sue Day
5Department of Epidemiology, School of Public Health, The University of Texas Health Science Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Imad Shureiqi
2Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
3Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ishureiq@med.umich.edu pyang@mdanderson.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The chemopreventive activity of celecoxib against colorectal cancer is limited to a proportion of familial adenomatous polyposis (FAP) patients who experience a response. The cause of this response variability and the potential mechanisms underlying these responses remain poorly understood. Preclinical studies showed that celecoxib increases the production of main oxidative metabolism product of linoleic acid, 13-S-hydroxyoctadecadienoic acid (13-S-HODE), to suppress colorectal tumorigenesis. We conducted a phase II clinical study to determine whether celecoxib increases 13-S-HODE production in colonic adenomas from FAP patients. Twenty seven FAP patients completed a 6-month oral course of 400 mg of celecoxib twice a day and had colonoscopies before and after celecoxib treatment to assess colorectal polyp tumor burden and obtain colorectal normal and polyp biopsies to measure celecoxib, 13-HODE, 15-HETE, 12-HETE, and LTB4 levels by LC/MS. Celecoxib levels in sera from those patients were also measured before treatment and 2, 4, and 6 months of treatment. Seventeen of the 27 patients experienced a response to celecoxib, with a more than 30% reduction of colonic polyp burden on the basis of a reproducible quantitative assessment of colonoscopy results. Celecoxib levels were significantly lower in polyp tissues than in normal colorectal tissues. Celecoxib levels in sera and normal colorectal tissues were correlated in patients who experienced a response to celecoxib but not in those who did not. Among the measured lipoxygenase products, only 13-HODE levels were significantly lower in polyp tissues than in normal tissues. Our findings demonstrate the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical response in FAP patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Cancer Institute (R01-CA106577 and R01-CA137213 to I.S., R01-CA144053 to P.Y, and R03-CA235106 to X. Z).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by UT MD Anderson Institutional Review Board, and all patients involved gave informed consent before participating. The study was also registered with ClinicalTrials.gov (number NCT00503035).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript are available by requested.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 04, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients
Peiying Yang, Xiangsheng Zuo, Shailesh Advani, Bo Wei, Jessica Malek, R. Sue Day, Imad Shureiqi
medRxiv 2020.12.02.20242214; doi: https://doi.org/10.1101/2020.12.02.20242214
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients
Peiying Yang, Xiangsheng Zuo, Shailesh Advani, Bo Wei, Jessica Malek, R. Sue Day, Imad Shureiqi
medRxiv 2020.12.02.20242214; doi: https://doi.org/10.1101/2020.12.02.20242214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (451)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5258)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (757)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (698)
  • Health Policy (358)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (163)
  • Infectious Diseases (except HIV/AIDS) (5872)
  • Intensive Care and Critical Care Medicine (362)
  • Medical Education (104)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (764)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (142)
  • Occupational and Environmental Health (233)
  • Oncology (479)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (862)
  • Public and Global Health (2012)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (285)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)